| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
18,565 |
9,009 |
$849K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,012 |
6,113 |
$448K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,041 |
6,813 |
$324K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,182 |
1,127 |
$108K |
| 88342 |
|
816 |
778 |
$47K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
237 |
192 |
$29K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
313 |
270 |
$23K |
| 88341 |
|
176 |
171 |
$16K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
113 |
73 |
$9K |
| 88313 |
|
138 |
128 |
$6K |
| 96127 |
|
1,867 |
1,671 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
185 |
110 |
$4K |
| 17000 |
|
124 |
100 |
$3K |
| 88307 |
|
27 |
27 |
$2K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
28 |
24 |
$2K |
| 17110 |
|
15 |
14 |
$788.77 |
| 93000 |
|
92 |
77 |
$693.19 |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
19 |
14 |
$652.47 |
| 71046 |
Radiologic examination, chest; 2 views |
32 |
26 |
$487.45 |
| 99406 |
|
74 |
44 |
$407.10 |
| 88304 |
|
12 |
12 |
$337.49 |
| 72100 |
|
16 |
14 |
$257.92 |
| 80053 |
Comprehensive metabolic panel |
23 |
19 |
$102.87 |
| 80061 |
Lipid panel |
16 |
12 |
$100.72 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
20 |
14 |
$77.21 |
| 1036F |
|
170 |
159 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
363 |
329 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
2,410 |
1,951 |
$0.00 |
| 1101F |
|
1,955 |
1,548 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
255 |
223 |
$0.00 |
| 3017F |
|
214 |
185 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
14 |
12 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
2,481 |
2,003 |
$0.00 |
| 4004F |
|
418 |
400 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
2,917 |
2,310 |
$0.00 |
| 1124F |
|
226 |
202 |
$0.00 |
| M1170 |
Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period |
26 |
20 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
103 |
99 |
$0.00 |
| 91300 |
|
18 |
12 |
$0.00 |
| 87631 |
|
82 |
59 |
$0.00 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
26 |
12 |
$0.00 |
| M1168 |
Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period |
16 |
13 |
$0.00 |
| M1176 |
Patient did not receive two doses of the herpes zoster recombinant vaccine (at least 28 days apart) on october 20, 2017, through the end of the measurement period |
20 |
15 |
$0.00 |